NCT07143149 Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China
| NCT ID | NCT07143149 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2025-11-03 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 4,000 participants in total. It began in 2025-11-03 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.
Eligibility Criteria
Inclusion Criteria 1. Age≥18 years as of the screening date; 2. Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date; 3. Prescribed Evolocumab at physician's discretion; 4. Signed informed consent. Exclusion Criteria: 1. Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.; 2. Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis); 3. Silent cerebral infarction without signs and symptoms; 4. Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date; 5. Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date; 6. Life expectancy \<12 months or unable to complete the research for other reasons as of the screening date; 7. Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders; 8. Refusal to participate in the enrollment survey.
Contact & Investigator
Yongjun Wang
STUDY DIRECTOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT07143149 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07143149 currently recruiting?
Yes, NCT07143149 is actively recruiting participants. Contact the research team at xujie@ncrcnd.org.cn for enrollment information.
Where is the NCT07143149 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07143149 clinical trial?
NCT07143149 is sponsored by Beijing Tiantan Hospital. The principal investigator is Yongjun Wang at Beijing Tiantan Hospital. The trial plans to enroll 4,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.